1175525-91-3

Usage

Uses

Used in Pharmaceutical Research:
[4-methoxy-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid ethyl ester is used as a reagent in organic synthesis for the development of pharmaceutical drugs. Its unique structure and properties make it a promising candidate for further research and development in the pharmaceutical industry.
Used in Chemical Research:
In the field of chemical research, [4-methoxy-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid ethyl ester is used as a building block for creating new compounds with potential applications in various industries. The presence of the boron-containing moiety in its structure makes it particularly interesting for potential applications in medicinal chemistry and drug discovery.
Used in Medicinal Chemistry:
[4-methoxy-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid ethyl ester is used as a key intermediate in the synthesis of complex organic molecules for medicinal chemistry. Its unique structure allows for the development of novel drugs with improved efficacy and reduced side effects.
Further research and studies are needed to explore the specific uses and potential benefits of [4-methoxy-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid ethyl ester in various industries.

Upstream product

• 774-81-2 (3-bromo-4-methoxy-phenyl)-acetic acid 
• 100125-96-0 (3-bromo-4-methoxy-phenyl)-acetic acid ethyl ester 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1175527-48-6 {2'-[(benzyloxycarbonyl-ethyl-amino)-methyl]-4'-methanesulfonyl-6-methoxy-biphenyl-3-yl}-acetic acid ethyl ester 
• 1219696-17-9 [3-(3-cyano-pyridin-2-yl)-4-methoxy-phenyl]-acetic acid ethyl ester 
• 1219696-23-7 (3-{3-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-5-methyl-pyridin-2-yl}-4-methoxy-phenyl)-acetic acid ethyl ester 
• 1219696-34-0 (3-{3-[(tert-butoxycarbonyl-ethyl-amino)-methyl]-quinolin-2-yl}-4-methoxy-phenyl)-acetic acid ethyl ester 
• 1185737-46-5 2-[6-methoxy-2'-((4S,5R)-4-methyl-2-oxo-5-phenyl-oxazolidin-3-ylmethyl)-4'-trifluoromethyl-biphenyl-3-yl]-propionic acid 
• 1445886-05-4 8-(5-carboxymethyl-2-methoxyphenyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid benzyl ester 
• 1445886-04-3 8-(5-carboxymethyl-2-methoxyphenyl)-5-cyano-3,4-dihydro-1H-isoquinoline-2-carboxylic acid benzyl ester 
• 1445885-89-1 8-(5-carboxymethyl-2-methoxyphenyl)-5-chloro-3,4-dihydro-1H-isoquinoline-2-carboxylic acid benzyl ester 
• 1185737-30-7 [6,4'-dimethoxy-2'-((4S,5R)-4-methyl-2-oxo-5-phenyl-oxazolidin-3-ylmethyl)-biphenyl-3-yl]-acetic acid 
• 1185737-24-9 [6-methoxy-2'-((4S,5R)-4-methyl-2-oxo-5-phenyl-oxazolidin-3-ylmethyl)-biphenyl-3-yl]-acetic acid 
• 1185737-27-2 [4'-fluoro-6-methoxy-2'-((4S,5R)-4-methyl-2-oxo-5-phenyl-oxazolidin-3-ylmethyl)-biphenyl-3-yl]-acetic acid 
• 1185737-53-4 [6-methoxy-2'-((4S,5R)-4-methyl-2-oxo-5-phenyl-oxazolidin-3-ylmethyl)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid ethyl ester 
• 1185737-41-0 [6-methoxy-2'-((4S,5R)-4-methyl-2-oxo-5-phenyl-oxazolidin-3-ylmethyl)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid 
• 1347747-37-8 C₂₆H₂₆F₃NO₃ 

Relevant academic research and scientific papers

PYRROLOPYRROLIDINONE COMPOUNDS

The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis

Biphenylacetic acid (5) was identified through a library screen as an inhibitor of the prostaglandin D2 receptor DP2 (CRTH2). Optimization for potency and pharmacokinetic properties led to a series of selective CRTH2 antagonists. Compounds demonstrated potency in a human DP2 binding assay and a human whole blood eosinophil shape change assay, as well as good oral bioavailability in rat and dog, and efficacy in a mouse model of allergic rhinitis following oral dosing.

DP2 Antagonist and Uses Thereof

Described herein is the DP2 antagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a

HETEROALKYL BIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGD2 receptors, alone and

HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are heteroaryl compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the heteroaryl compounds described. Also described herein are methods of using such antagonists o

ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGD2 receptors described herein, as well as methods of using such a

N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.